668 completed, 186 terminated, 142 recruiting, 108 unknown. 1285 Phase 2, 251 Phase 1, 61 Phase 3.
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer Clomiphene Citrate 25mg - Prostate Cancer | Phase 2 | Not yet recruiting | University of Nebraska | 83 | 2027-01-31 | 2026-10-20 |
| Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 96 | 2026-12-31 | 2026-10-22 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-05 | 2026-11-02 |
| Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance TriAdeno vaccine, N-803 - Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 52 | 2026-11-05 | 2026-11-02 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-05 | 2026-11-02 |
| Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE PSMA 99mTc-MIP-1404 radioguided salvage lymph node dissection, Salvage pelvic lymph node dissection - Prostate Cancer, Oligometastatic | Phase 2 | Not yet recruiting | University of British Columbia | 62 | 2026-11-01 | 2026-09-08 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo - Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 30 | 2026-11-01 | 2026-09-02 |
| [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq - Metastatic Prostate Cancer, Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 75 | 2026-11-01 | 2026-10-21 |
| Adaptive Radiotherapy for Safe Hypofractionation Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy - Cancer, Endometrial Cancer | Phase 2 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 264 | 2026-11-01 | 2026-10-29 |
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) Fezolinetant, Placebo - Vasomotor Symptoms, Prostate Cancer | Phase 2 | Recruiting | Chinese University of Hong Kong | 54 | 2026-10-05 | 2026-10-07 |
| IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy N-803, ETBX-71 Vaccine, 18F-DCFPyL - Recurrent Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2026-10-01 | 2026-10-06 |
| LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan Xaluritamig - Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Not yet recruiting | Thomas Jefferson University | 30 | 2026-10-01 | 2026-08-14 |
| Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study [68Ga]Ga-OncoACP3 - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Not yet recruiting | Yong He | 50 | 2026-10-01 | 2026-09-23 |
| Study of Boswellia for Urinary Toxicity in Prostate Cancer Radiotherapy Boswellia serrata extract - Prostate Cancer | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 20 | 2026-10-01 | 2026-10-09 |
| Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup]) [68Ga]-LNTH-2401 - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Lantheus Medical Imaging | 408 | 2026-09-30 | 2026-09-21 |
| Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer PSMAxCD3, bispecific antibody CC-1, Multipeptide Vaccine VAC-XS15-PC01 - Prostate Cancer | Phase 2 | Recruiting | University Hospital Tuebingen | 84 | 2026-09-24 | 2026-10-06 |
Showing 20 of 1285. Sign in to see all of them.
Prostatic Neoplasms (1285) · Neoplasm Metastasis (69) · Neoplasms (58) · Breast Neoplasms (53) · Carcinoma, Non-Small-Cell Lung (35) · Ovarian Neoplasms (29) · Lung Neoplasms (26) · Colorectal Neoplasms (22) · Pancreatic Neoplasms (21) · Urinary Bladder Neoplasms (20) · Stomach Neoplasms (19) · Esophageal Neoplasms (17) · Endometrial Neoplasms (16) · Head and Neck Neoplasms (15) · Melanoma (15)
Urogenital Diseases (1284) · Genital Diseases (1283) · Genital Diseases, Male (1281) · Male Urogenital Diseases (1279) · Neoplasms by Site (1279) · Genital Neoplasms, Male (1277) · Prostatic Diseases (1275) · Urogenital Neoplasms (1275) · Neoplasms (1227) · Pathological Conditions, Signs and Symptoms (115) · Pathologic Processes (94) · Neoplastic Processes (72) · Female Urogenital Diseases (65) · Female Urogenital Diseases and Pregnancy Complications (65) · Skin Diseases (63)
Docetaxel (118) · Prednisone (93) · Leuprolide (69) · Abiraterone Acetate (59) · enzalutamide (59) · Radiotherapy (47) · bicalutamide (46) · Goserelin (43) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (40) · Androgen Antagonists (36) · abiraterone (29) · Estramustine (27) · gallium 68 PSMA-11 (24) · Gonadotropin-Releasing Hormone (23) · apalutamide (23)
Memorial Sloan Kettering Cancer Center (46) · National Cancer Institute (NCI) (43) · M.D. Anderson Cancer Center (35) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (27) · Dana-Farber Cancer Institute (21) · University of Wisconsin, Madison (18) · University Health Network, Toronto (16) · Ferring Pharmaceuticals (15) · University of Michigan Rogel Cancer Center (15) · Alliance for Clinical Trials in Oncology (14) · University of California, San Francisco (14) · Duke University (13) · Weill Medical College of Cornell University (12) · OHSU Knight Cancer Institute (11) · AstraZeneca (10)
United States (850) · Canada (130) · United Kingdom (76) · France (64) · China (59) · Germany (42) · Italy (40) · Spain (37) · Belgium (35) · Australia (34) · Netherlands (31) · Switzerland (19) · Czechia (17) · South Korea (17) · Poland (16)
Mary-Ellen Taplin, MD (10) · Donald L. Trump, MD (6) · Michael Morris, MD (6) · Rahul Aggarwal, MD (6) · Ravi A Madan, M.D. (6) · Chadi Nabhan, MD (5) · Christopher Logothetis, MD (4) · Daniel George, MD (4) · David C. Smith, MD (4)
PMID 25712310, PMID 32994091, PMID 33270906, PMID 33465252, PMID 22747660, PMID 24412228, PMID 24722180, PMID 24974051, PMID 25475068, PMID 25614256, PMID 25687533, PMID 25786708, PMID 25936597, PMID 25963190, PMID 34350976, PMID 34529005, PMID 35027313, PMID 36001857, PMID 37482512, PMID 38421252, PMID 39074346, PMID 40645505, PMID 42186347, PMID 10661346, PMID 11106233, PMID 11828001, PMID 11857298, PMID 12142053, PMID 12506177, PMID 12610188, PMID 12627508, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14669278, PMID 14871968, PMID 14967428, PMID 15042609, PMID 15054447, PMID 15139054, PMID 15169798, PMID 15464920, PMID 15590164, PMID 15659491, PMID 15735119, PMID 15936549, PMID 15989995, PMID 16006888, PMID 16138006, PMID 16289906
2017 (11), 2016 (10), P30CA072720 (8), U10CA031946 (8), P30CA022453 (6), P30CA043703 (6), 2019 (5), 2023 (5), P30CA012197 (5), 2005 (4), 2009 (4), P30CA016672 (4), 2014 (3), P30CA015083 (3), P50CA090270 (3)